Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | VDR | P11473 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL766861 | 1.00 | CA2 (0.44) | CA2CA9CA12GAAALDH1A1 | |
| SCHEMBL3838479 | 1.00 | CA2 (0.44) | CA2CA9CA12GAAALDH1A1 | |
| SCHEMBL5831287 | 0.87 | GAA (0.45) | CA2CA9CA12GAAALDH1A1 | |
| SCHEMBL18737643 | 0.87 | GAA (0.45) | CA2CA9CA12GAAALDH1A1 | |
| SCHEMBL16424498 | 0.87 | GAA (0.45) | CA2CA9CA12GAAALDH1A1 | |
| SCHEMBL17404667 | 0.87 | GAA (0.45) | CA2CA9CA12GAAALDH1A1 | |
| SCHEMBL5245093 | 0.87 | GBA1 (0.46) | CA2CA9CA12GAAALDH1A1 | |
| SCHEMBL10932836 | 0.87 | GBA1 (0.46) | CA2CA9CA12GAAALDH1A1 | |
| SCHEMBL5830519 | 0.87 | GBA1 (0.46) | CA2CA9CA12GAAALDH1A1 | |
| SCHEMBL14778372 | 0.87 | GAA (0.45) | CA2CA9CA12GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119381549-A | Electrolyte for improving low-temperature performance and preparation method and application thereof | 湖南法恩莱特新能源科技有限公司 | 2025-01-28 | — | — | CN | claimed |
| CN-118501280-A | Detection method and application of sulfonate impurities in bulk drug | 上海市计量测试技术研究院(中国上海测试中心、华东国家计量测试中心、上海市计量器具强制检定中心) | 2024-08-16 | — | — | CN | claimed |
| CN-117890516-A | Method for detecting benzenesulfonate genotoxic impurities in cisatracurium besylate drug | 白璧炜 | 2024-04-16 | — | — | CN | claimed |
| CN-111793193-A | Solvent-free type 180-DEG C-resistant ultralow-viscosity epoxy resin matrix and preparation method thereof | 黑龙江省科学院石油化学研究院 | 2020-10-20 | — | — | CN | claimed |
| EP-2579377-B1 | NONAQUEOUS ELECTROLYTE SOLUTION AND ELECTROCHEMICAL ELEMENT USING SAME | UBE INDUSTRIES (JP) | 2014-09-03 | — | — | EP | claimed |
| US-4523208-A | SULFONIC ACID ESTER AS ACTIVATOR | BASF AKTIENGESELLSCHAFT (DE) | 1985-06-11 | — | — | US | claimed |
| CN-113891879-B | 3, 6-Disubstituted-2-pyridine aldoxime skeleton | 国家科学研究中心 | 2025-03-04 | — | — | CN | disclosed |
| US-20250041306-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS INC. (CN) | 2025-02-06 | — | — | US | disclosed |
| CN-119381549-A | Electrolyte for improving low-temperature performance and preparation method and application thereof | 湖南法恩莱特新能源科技有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-119343353-A | 2-Methyl-4 ',5' -dihydrospiro [ piperidine-4, 7' -thieno [2,3-c ] pyran ] derivatives as APOL1 inhibitors and methods of use thereof | 弗特克斯药品有限公司 | 2025-01-21 | — | — | CN | disclosed |
| WO-2024228580-A1 | NOVEL HETEROCYCLIC AMINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 대웅제약 | 2024-11-07 | — | — | WO | disclosed |
| US-20240300899-A1 | A QUINOLONE COMPOUND IN SOLID FORMS AND PROCESSES FOR THE PREPARATION THEREOF | ZYDUS LIFESCIENCES LIMITED (IN) | 2024-09-12 | — | — | US | disclosed |
| CN-118501280-A | Detection method and application of sulfonate impurities in bulk drug | 上海市计量测试技术研究院(中国上海测试中心、华东国家计量测试中心、上海市计量器具强制检定中心) | 2024-08-16 | — | — | CN | disclosed |
| US-5271866-A | Liquid-crystalline polymer composition | IDEMITSU KOSAN CO., LTD. (JP) | 1993-12-21 | — | — | US | disclosed |
| US-5269963-A | Liquid-crystalline polymer composition | IDEMITSU KOSAN CO., LTD. (JP) | 1993-12-14 | — | — | US | disclosed |
| EP-0297554-B1 | LIQUID-CRYSTALLINE POLYMER COMPOSITION | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1993-09-22 | — | — | EP | disclosed |
| WO-1993009114-A1 | TRI-SUBSTITUTED TETRAHYDROFURAN ANTIFUNGALS | SCHERING CORPORATION (US) | 1993-05-13 | — | — | WO | disclosed |
| EP-0539938-A1 | Tri-substituted tetrahydrofuran antifungals | SCHERING CORPORATION (US) | 1993-05-05 | — | — | EP | disclosed |
| US-5034153-A | Liquid-crystalline polymer composition | IDEMITSU KOSAN CO., LTD. (JP) | 1991-07-23 | — | — | US | disclosed |
| EP-0297554-A2 | Liquid-crystalline polymer composition | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1989-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250041306-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | ADAMTS1, UCHL3, ADAM33 | CA2 4465/4885CA9 2383/4885CA12 2074/4885 |
| US-20240300899-A1 | A QUINOLONE COMPOUND IN SOLID FORMS AND PROCESSES FOR THE PREPARATION THEREOF | NQO2, SQLE, RECQL | CA2 3424/4885CA9 2451/4885CA12 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.